Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC

Authors:

Abstract
No abstract available
Funding Information
  • Pfizer
  • Takeda Pharmaceuticals U.S.A.
  • AstraZeneca
  • Merck KGaA
  • GlaxoSmithKline
  • Merck Sharp and Dohme United Kingdom
  • Roche
  • Karyopharm Therapeutics
  • Bristol-Myers Squibb
  • Astellas Pharma Global Development
  • Spectrum Pharmaceuticals
  • MedImmune
  • National Cancer Institute (1U01CA231844-01, 200858, NCT02034123)
  • AbbVie
  • Boehringer Ingelheim
  • Meso Scale Diagnostics
  • Amgen
  • Ipsen Biopharmaceuticals
  • Sanofi
  • Clovis Oncology
  • Johnson & Johnson Innovative Medicine
  • Daiichi Sankyo Company

This publication has 24 references indexed in Scilit: